KPV is a tri-peptide derived from a natural occurring hormone in the body called alpha-melanocyte-stimulating-hormone that exhibits anti-inflammatory, anti-microbial, and immunomodulating benefits. KPV exerts its anti-inflammatory function inside cells, where it inactivates inflammatory pathways. KPV can enter the cell and interact directly with inflammatory signaling molecules. It enters the nucleus of the cell and once it’s there, it can inhibit the inflammatory substances and molecules. Research shows that KPV is effective in decreasing inflammation in the GI system by inhibiting proinflammatory cytokine mechanisms in both intestinal epithelial cells and immune cells. This makes KPV very effective in treatment for a variety of inflammatory bowel diseases, Chron's disease, and colitis.
KPV also expresses a strong anti-microbial and anti-fungal effect. Research has shown a strong killing effect on both Staphylococcus aureus bacteria and the Candida Albicans. KPV's effect of both decreasing inflammation in the GI system along with its strong anti-microbial and anti-fungal effects make it a perfect peptide treatment for healing and strengthening gastrointestinal system and immune system function.
Anti-inflammatory: Systemically and GI specific
Strengthen Immune System Function
Decrease Joint and Muscle Pain
Improved Gut Health
Improve Skin Health
Protect against Nerve Damage
Protects against Stroke
Decrease Intestinal Inflammation
Decreased Scar Formation
KPV is safe to use
Research shows that KPV has an excellent safety profile with no documented side effects.
KPV is an oral capsule that is administered one time daily on an empty stomach.
Research and References
1. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3(Suppl 3):iii52-iii55. doi:10.1136/ard.2007.079780
2. Cutuli, M., Cristiani, S., Lipton, J. M., & Catania, A. (2000). Antimicrobial effects of alpha-MSH peptides. Journal of leukocyte biology, 67(2), 233–239. https://doi.org/10.1002/jlb.67.2.233.
3. Dalmasso, G., et al. (2008). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology, 134(1), 166–178. DOI: 10.1053/j.gastro.2007.10.026
4. Klaus Kannengiesser, MD, Christian Maaser, MD, Jan Heidemann, MD, Andreas Luegering, MD, Matthias Ross, MD, Thomas Brzoska, PhD, Markus Bohm, MD, Thomas A. Luger, MD, Wolfram Domschke, MD, Torsten Kucharzik, MD, Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, Inflammatory Bowel Diseases, Volume 14, Issue 3, 1 March 2008, Pages 324–331, https://doi.org/10.1002/ibd.20334.
5. Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010;681:107-16. doi: 10.1007/978-1-4419-6354-3_8. PMID: 21222263.
6. Luger TA, Bohm M. Are melanocortin peptides future therapeutics for cutaneous wound healing? Experimental Derm. 20 January 2019. https://doi.org/10.1111/exd.13887
7. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008 Aug;29(5):581-602. doi: 10.1210/er.2007-0027. Epub 2008 Jul 8. PMID: 18612139.
8. Sarkar A, Sreenivasan Y, Manna SK 2003 α-Melanocyte-stimulating hormone induces cell death in mast cells: involvement of NF-κB. FEBS Lett 549:87–93.
9. Redondo P, García-foncillas J, Okroujnov I, Bandrés E. Alpha-MSH regulates interleukin-10 expression by human keratinocytes. Arch Dermatol Res. 1998;290(8):425-8.
10. Mehta D, Granstein R, D: Immunoregulatory Effects of Neuropeptides on Endothelial Cells: Relevance to Dermatological Disorders. Dermatology 2019;235:175-186. doi: 10.1159/000496538
11. Sinha PS, Schiöth HB, Tatro JB. Roles of the melanocortin-4 receptor in antipyretic and hyperthermic actions of centrally administered alpha-MSH. Brain Res. 2004;1001(1-2):150-8
12. Elliott R J, Szabo M, Wagner M J, Kemp E H, MacNeil S, Haycock J W. alpha‐Melanocyte‐stimulating hormone, MSH 11‐13 KPV and adrenocorticotropic hormone signaling in human keratinocyte cells. J Invest Dermatol 20041221010–1019.
13. Van de meent H, Hamers FP, Lankhorst AJ, Joosten EA, Gispen WH. Beneficial effects of the melanocortin alpha-melanocyte-stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury. Neurosurgery. 1997;40(1):122-30
14. Abdel-malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J. 2006;20(9):1561-3
15. Bohm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2005;280(7):5795-802
16. Lam C W, Getting S J. Melanocortin receptor type 3 as a potential target for anti‐inflammatory therapy. Curr Drug Targets Inflamm Allergy 20043311–315.
17. Taylor AW, Yee DG, Nishida T, Namba K. Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH). Ann N Y Acad Sci. 2000;917:239-47
18. 3. Rajora N, Boccoli G, Catania A, et al. α-MSH modulates experimental inflammatory bowel disease. Peptides. 1997;18:381–385.